| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $2,064,367 ) |
| | 2025 | 2025 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21AI178352 | Delineating host response to central venous catheter associated Candida albicans biofilm infections, and development of novel therapeutics to combat drug resistant biofilms | 000 | 2 | NIH | 2/28/2025 | $198,554 |
| | 2025 | 2025 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502 | LOS ANGELES | USA | R61HD114186 | IND-enabling studies to develop triptonide into the first nonhormonal male pill | 001 | 2 | NIH | 4/16/2025 | $35,344 |
| | 2025 | 2025 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R61HD114186 | IND-enabling studies to develop triptonide into the first nonhormonal male pill | 000 | 2 | NIH | 1/13/2025 | $318,099 |
| | 2025 | 2025 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01NS131646 | Defining cerebellar pathophysiology in Ataxia Telangiectasia | 000 | 2 | NIH | 1/22/2025 | $574,684 |
| | 2025 | 2025 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01DK136888 | Spatiotemporal regulation of human islet organogenesis | 000 | 2 | NIH | 2/28/2025 | $541,560 |
| | 2025 | 2025 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502 | LOS ANGELES | USA | R01CA288736 | Deciphering functions of the ATR-METTL3-BRCA1 Axis in genome instability and Tumorigenesis | 000 | 2 | NIH | 4/24/2025 | $414,013 |
| | 2025 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502 | LOS ANGELES | USA | R21AI169276 | Targeting evolutionarily acquired insertion sequences in Candida species, for development of antifungal drugs | 000 | 2 | NIH | 4/29/2025 | -$16,873 |
| | 2025 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502 | LOS ANGELES | USA | R01HL155104 | Type I IFN signaling during lung development in Down Syndrome | 003 | 2 | NIH | 4/2/2025 | $485,463 |
| | 2025 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | U19AI172713 | Systems Epigenomics of Persistent Bloodstream Infection | 000 | 2 | NIH | 10/17/2024 | $0 |
| | 2025 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502 | LOS ANGELES | USA | R01AI139244 | The role of purine biosynthesis and stringent response in persistent MRSA endovascular infections | 000 | 5 | NIH | 5/7/2025 | $0 |
| | 2025 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI146078 | Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical Translatability | 000 | 5 | NIH | 1/8/2025 | $0 |
| | 2025 | 2023 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21AI159221 | Unraveling transcriptomic and functional changes to immune sensing neuronal ganglia in response to allergy and bacteria | 000 | 2 | NIH | 11/22/2024 | -$13 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI141794 | Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasis | 000 | 4 | NIH | 2/10/2025 | -$621 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502 | LOS ANGELES | USA | R01HL155104 | Type I IFN signaling during lung development in Down Syndrome | 002 | 1 | NIH | 4/2/2025 | -$352,785 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HL155104 | Type I IFN signaling during lung development in Down Syndrome | 000 | 1 | NIH | 11/22/2024 | $0 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21HD104028 | Prevention of obesity in Infants of overweight and obese women | 001 | 2 | NIH | 12/29/2024 | $0 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21HD104028 | Prevention of obesity in Infants of overweight and obese women | 000 | 2 | NIH | 10/9/2024 | $0 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | U01AI116400 | Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment | 001 | 5 | NIH | 11/20/2024 | $0 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | U01AI116400 | Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment | 000 | 5 | NIH | 10/24/2024 | $0 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HL141856 | Mechanisms controlling early human lung development | 000 | 6 | NIH | 11/12/2024 | $0 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | K01HL141697 | Newborn Screening for Critical Congenital Heart Disease in U.S.: Assessment of implementation obstacles and application of cost-effectiveness to gauge if action needed for improved implementation | 000 | 5 | NIH | 11/7/2024 | $0 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502 | LOS ANGELES | USA | R61NS119708 | Optimizing Small Molecule Read-Through Compounds for Treating AtaxiaTelangiectasia | 000 | 1 | NIH | 3/25/2025 | $0 |
| | 2025 | 2022 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21HD105170 | Disparities in the effect of state policy for the newborn screening for critical congenital heart diseases | 000 | 2 | NIH | 12/29/2024 | -$380 |
| | 2025 | 2021 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502 | LOS ANGELES | USA | R01HL155104 | Type I IFN signaling during lung development in Down Syndrome | 001 | 1 | NIH | 4/2/2025 | -$132,678 |
|
| Issue Date FY: 2024 ( Subtotal = $11,889,444 ) (Continued on the next page) |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21AI178352 | Delineating host response to central venous catheter associated Candida albicans biofilm infections, and development of novel therapeutics to combat drug resistant biofilms | 000 | 1 | NIH | 3/7/2024 | $227,776 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01DK136888 | Spatiotemporal regulation of human islet organogenesis | 000 | 1 | NIH | 3/15/2024 | $601,734 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21MH137745 | Suicidal Behavior among Adolescents Experiencing Homelessness in the US during the COVID-19 Pandemic | 000 | 1 | NIH | 8/1/2024 | $259,773 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | K01AI180591 | Role of multi-drug resistant Candida auris Hyr1 / Iff-like proteins in virulence and their potential as vaccine targets | 000 | 1 | NIH | 7/18/2024 | $134,800 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01DK132875 | Plant-Focused Nutrition in Patients with Diabetes and Chronic Kidney Disease (PLAFOND Study): A Pilot/Feasibility Study | 000 | 2 | NIH | 8/1/2024 | $266,294 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01CA288736 | Deciphering functions of the ATR-METTL3-BRCA1 Axis in genome instability and Tumorigenesis | 000 | 1 | NIH | 5/30/2024 | $460,015 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R13HD115366 | Celebrating the Inspired and Inspiring Testis Biology- The XXVII North American Testis Workshop | 000 | 1 | NIH | 2/28/2024 | $2,000 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R13HD115366 | Celebrating the Inspired and Inspiring Testis Biology- The XXVII North American Testis Workshop | 000 | 1 | NIH | 2/28/2024 | $8,000 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R24OD037736 | BRC Modernization of Sterilizing Equipment | 000 | 1 | NIH | 8/5/2024 | $128,500 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | U19AI172713 | Systems Epigenomics of Persistent Bloodstream Infection | 000 | 2 | NIH | 5/17/2024 | $2,344,235 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HD109286 | Tryptophan metabolism and its role in fibroid pathogenesis | 000 | 3 | NIH | 6/10/2024 | $381,398 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HL166850 | Novel cardiopulmonary exercise testing variables to differentiate neuromuscular deconditioning from disease | 000 | 2 | NIH | 9/7/2024 | $769,307 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01DE031382 | Oral commensal fungi and structural immunity | 000 | 3 | NIH | 5/29/2024 | $497,444 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HL155104 | Type I IFN signaling during lung development in Down Syndrome | 000 | 2 | NIH | 6/24/2024 | $557,095 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | P50HD098593 | Center for Male Reproductive Epigenomics | 001 | 5 | NIH | 5/13/2024 | $1,438,718 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01NS131646 | Defining cerebellar pathophysiology in Ataxia Telangiectasia | 000 | 1 | NIH | 1/4/2024 | $584,891 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R56AI175328 | Asthmatic inflammation requires neuronal upregulation of B-cells | 001 | 1 | NIH | 7/16/2024 | $33,200 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R56AI175328 | Asthmatic inflammation requires neuronal upregulation of B-cells | 000 | 1 | NIH | 3/5/2024 | $298,800 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21AI169276 | Targeting evolutionarily acquired insertion sequences in Candida species, for development of antifungal drugs | 001 | 2 | NIH | 5/13/2024 | $25,602 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21AI169276 | Targeting evolutionarily acquired insertion sequences in Candida species, for development of antifungal drugs | 000 | 2 | NIH | 10/25/2023 | $230,423 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R21AI178352 | Delineating host response to central venous catheter associated Candida albicans biofilm infections, and development of novel therapeutics to combat drug resistant biofilms | 001 | 1 | NIH | 9/11/2024 | $25,309 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01AI162802 | Transcriptional networks governing A. fumigatus virulence | 000 | 4 | NIH | 8/12/2024 | $657,546 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST BLDG MRL | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HL171915 | Cellular Senescence in Trisomy 21 lung disease | 000 | 1 | NIH | 9/1/2024 | $625,799 |
| | 2024 | 2024 | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 1124 W CARSON ST | TORRANCE | CA | 90502-2006 | LOS ANGELES | USA | R01HD099924 | Epitranscriptomic regulation of spermatogenesis and male fertility | 000 | 5 | NIH | 5/1/2024 | $372,275 |
|
